Two Onc Docs

This week’s episode will be focusing on an update of a late-breaking abstract presented at ASH 2025 this past week: the Phase 3 BRUIN-CLL 313 trial looking at Pirtobrutinib vs Bendamustine/Rituximab in 1L Chronic Lymphocytic Leukemia (CLL).

This week’s episode will be focusing on gastrointestinal stromal tumors, known as GIST with a 2025 update. We will go over important details on the diagnosis, mutations, and treatment of local and metastatic GISTs.  

This week’s episode is also due for an update since it aired in 2022. Will be focusing on Hodgkin Lymphoma (HL), both classical and nodular lymphocyte-predominant. We will go into important details on the pathology, staging, Deauville scoring, and treatment for early stage/advanced stage as well as relapsed and refractory HL.

Today’s episode is focusing on what you need to know regarding Anal cancer. This was one of our first episodes back in 2022 so it is time for an updated episode! This will include the important details on risk factors, diagnostic work-up, staging and treatment of both localized and metastatic anal cancer.

This week’s episode will be on many exciting updates were announced at ESMO this October in Berlin from Oct 17-21, 2025, especially in bladder cancer, we continue to make such progress! We discuss key trials in NMIBC (POTOMAC), MIBC (KN-905, IMvigor-011), and metastatic urothelial carcinoma (FORAGER-1, DV + Toripalimab).